Archives of Medical Research
Volume 41, Issue 2 , Pages 104-109 , February 2010

Apolipoprotein, C-Reactive Protein and Oxidative Stress Parameters in Dyslipidemic Type 2 Diabetic Patients Treated or Not with Simvastatin

  • Vanusa Manfredini

      Affiliations

    • Programa de Pós-Graduação em Ciências Farmacêuticas da Universidade Federal do Rio Grande do Sul, Brazil
    • ,
  • Giovana Brondani Biancini

      Affiliations

    • Serviço de Genética Médica, Laboratório de Análise de Metabólitos (LAM), Hospital de Clínicas de Porto Alegre, Brazil
    • ,
  • Camila Simioni Vanzin

      Affiliations

    • Serviço de Genética Médica, Laboratório de Análise de Metabólitos (LAM), Hospital de Clínicas de Porto Alegre, Brazil
    • ,
  • Anna Maria Ribeiro Dal Vesco

      Affiliations

    • Serviço de Genética Médica, Laboratório de Análise de Metabólitos (LAM), Hospital de Clínicas de Porto Alegre, Brazil
    • ,
  • Carlos Alberto Yasin Wayhs

      Affiliations

    • Programa de Pós-Graduação em Ciências Farmacêuticas da Universidade Federal do Rio Grande do Sul, Brazil
    • ,
  • Maria do Carmo Ruaro Peralba

      Affiliations

    • Instituto de Química Inorgânica da Universidade Federal do Rio Grande do Sul (UFRGS), Brazil
    • ,
  • Carmen Regla Vargas

      Affiliations

    • Programa de Pós-Graduação em Ciências Farmacêuticas da Universidade Federal do Rio Grande do Sul, Brazil
    • Serviço de Genética Médica, Laboratório de Análise de Metabólitos (LAM), Hospital de Clínicas de Porto Alegre, Brazil
    • Programa de Pós-Graduação em Ciências Biológicas Bioquímica, Brazil
    • Corresponding Author InformationAddres reprint requests to: Carmen Regla Vargas, Serviço de Genética Médica, Hospital de Clínicas de Porto Alegre, R: Ramiro Barcelos, 2350, Bairro: Bom Fim, Porto Alegre RS, Brazil, 90035-003; Phone: (+55) (51) 3359 8011

Received 15 September 2009 ,Accepted 13 February 2010.

References 

  1. Guillausseau PJ, Meas T, Virally M, et al. Abnormalities in insulin secretion in type 2 diabetes mellitus. Diabetes Metab. 2008;34:S43–S48
  2. Schleiffer T, Holken H, Brass H. Morbidity in 565 type 2 diabetic patients according to stage of nephropathy. J Diabetes Complications. 1998;12:103–109
  3. Solano MP, Goldberg RB. Lipid management in type 2 diabetes. Clin Diabet. 2006;24:27–32
  4. Iwase M, Kazuo S, Nobuhiro S, et al. Lysophosphatidylcholine contents in plasma LDL in patients with type 2 diabetes mellitus: relation with lipoprotein-associated phospholipase A2 and effects of simvastatin treatment. Atherosclerosis. 2008;196:931–936
  5. Halliwell B, Gutteridge JMC. Cellular responses to oxidative stress: adaptation, damage, repair, senescence and death. In:  Halliwell B,  Gutteridge JMC editor. Free Radicals in Biology and Medicine. 3rd ed. New York: Oxford University Press; 2007;p. 187–267
  6. Griesmacher A, Kindhauser M, Andert SE, et al. Enhanced serum levels of thiobarbituric acid-reactive substances in diabetes mellitus. Am J Med. 1995;98:469–475
  7. Telci A, Cakatay U, Kayali R, et al. Oxidative protein damage in plasma of type 2 diabetic patients. Hormone Metab Res. 2000;32:40–43
  8. Antunes F, Salvador A, Marinho HS, et al. Lipid peroxidation in mitochondrial inner membranes. I. An integrative kinetic model. Free Radic Biol Med. 1996;21:917–943
  9. Levine RL. Oxidative modification of glutamine synthetase 1. Inactivation is due to loss of one histidine residue. J Biol Chem. 1983;258:11823–11827
  10. Beal MF. Oxidatively modified proteins in aging and disease. Free Radic Biol Med. 2002;32:797–803
  11. Dalle-Donne I, Rossi R, Giustarini D, et al. Protein carbonyl groups as biomarkers of oxidative stress. Clin Chim Acta. 2003;329:23–38
  12. Cakatay U. Protein oxidation parameters in type 2 diabetic patients with good and poor glycaemic control. Diabetes Metab. 2005;31:551–557
  13. Al-Bahrani AI, Bakhiet CS, Bayoumi RA, et al. A potential role of apolipoprotein B in the risk stratification of diabetic patients with dyslipidaemia. Diabetes Res Clin Pract. 2005;69:44–51
  14. Tsuzura S, Ikeda Y, Suehiro T, et al. Correlation of plasma oxidized low-density lipoprotein levels to vascular complications and human serum paraoxonase in patients with type 2 diabetes. Metabolism. 2004;53:297–302
  15. Karatepe M. Simultaneous determination of ascorbic acid and free malondialdehyde in human serum by HPLC-UV. LCGC North Am. 2004;22:362–365
  16. Levine RL, Garland D, Oliver CN, et al. Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol. 1990;186:464–478
  17. Ellman LG. Tissue sulfhydryl groups. Arch Biochem Biophys. 1959;82:70–77
  18. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414:782–787
  19. Kurian KC, Ral P, Sankaran S, et al. The effect of statins in heart failure: beyond its cholesterol-lowering effect. J Cardiac Failure. 2006;12:473–478
  20. Saha A, Adak S, Chowdhury S, et al. Enhanced oxygen releasing capacity and oxidative stress in diabetes mellitus and diabetes mellitus-associated cardiovascular disease: a comparative study. Clin Chim Acta. 2005;361:141–149
  21. Deuticke B. The role of membrane sulfhydryls in passive, mediated transport processes and for the barrier functions of the erythrocyte membrane. Membrane Biochem. 1986;6:309–326
  22. Aviram M. Oxidized low density lipoprotein (ox-LDL) interaction with macrophages in atherosclerosis and the atherogenicity of antioxidants. Eur J Clin Chem Clin Biochem. 1996;34:599–608
  23. Onat A, Can G, Hergenç G. Serum C-reactive protein is an independent risk factor predicting cardiometabolic risk. Metabol Clin Exp. 2008;57:207–214
  24. Shishehbor MH, Brennan M-L, Aviles RJ, et al. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA. 2003;289:1675–1680
  25. Shishehbor MH, Brennan M-L, Aviles RJ, et al. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation. 2003;108:426–431
  26. Laufs U, La Fata V, Plutzky J, et al. Upregulation of endothelial nitric oxide synthase by HMG-CoA recdutase inhibitors. Circulation. 1999;97:1129–1135
  27. O'Donnell VB, Chumley PH, Hogg N, et al. Nitric oxide inhibition of lipid peroxidation: kinetics of reaction with lipid peroxyl radicals and comparison with alpha-tocopherol. Biochemistry. 1997;36:15216–15223
  28. Wagner HA, Kobler T, Ruckschloss U, et al. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA recdutase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol. 2000;20:61–69

PII: S0188-4409(10)00031-7

doi: 10.1016/j.arcmed.2010.03.006

Archives of Medical Research
Volume 41, Issue 2 , Pages 104-109 , February 2010

Article Tools

* Image Usage & Resolution